Shots:
- Teva Pharmaceuticals and mAbxience have signed a strategic licensing agreement across various markets incl. the EU and the US to develop a biosimilar product that is under development as a treatment for various oncology indications
- As per the agreement, mAbxience will develop and produce the candidates by utilizing the knowledge of biosimilar development & its state-of-the-art along with current Good Manufacturing Practice (cGMP)-approved facilities in Spain & Argentina
- Furthermore, Teva will be responsible for all the regulatory and commercialization activities across the designated areas for easy access to the patients
Ref: Teva Pharmaceuticals and mAbxience | Image: Teva Pharmaceuticals and mAbxience | Press Release
Related News:- Mabwell’s Maiweijian (Biosimilar, Denosumab; 120mg) Receives the NMPA approval for Marketing Authorization in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
